Eplerenone Shortage: What Providers and Prescribers Need to Know in 2026

Eplerenone is a cornerstone of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) following myocardial infarction, and an important agent for resistant and secondary hypertension. While there is no declared FDA drug shortage as of 2026, prescribers are increasingly fielding calls from patients who cannot fill their Eplerenone prescriptions due to insurance barriers, cost issues, and intermittent pharmacy-level stock gaps. This clinical briefing covers what you need to know and what you can do.

Current Supply Status: No National Shortage

As of early 2026, Eplerenone is not listed on the FDA Drug Shortage Database or the ASHP Drug Shortage Database. Generic Eplerenone is manufactured by multiple companies and distributed broadly. Brand-name Inspra (Viatris) is also available. The supply chain for Eplerenone is stable, and manufacturing disruptions are not the primary driver of patient access complaints.

The more common issues providers will encounter involve: formulary restrictions and prior authorization requirements, cost barriers for uninsured or underinsured patients, and temporary pharmacy-level stock variability — particularly in rural or lower-volume pharmacies.

Clinical Context: Why Continuity Matters

For post-MI HFrEF patients, Eplerenone reduces all-cause mortality and cardiovascular hospitalization when used as part of GDMT. The landmark EPHESUS trial demonstrated significant survival benefit. The 2022 AHA/ACC/HFSA Heart Failure Guidelines give a Class I, Level B-R recommendation for mineralocorticoid receptor antagonists (MRAs) in patients with HFrEF (LVEF ≤40%) to reduce morbidity and mortality. Interruptions in therapy — even brief ones — may compromise clinical outcomes in high-risk patients.

Formulary and Insurance Barriers

Despite being a generic, Eplerenone faces formulary obstacles that its older counterpart (spironolactone) does not. Many commercial plans and some Medicare Part D plans place Eplerenone on Tier 2 or Tier 3 with prior authorization or step therapy requirements — often requiring a trial of spironolactone first.

Prescribing strategies to minimize insurance friction:

Document the clinical reason for Eplerenone over spironolactone in the chart — particularly if the patient has a history of gynecomastia, sexual dysfunction, or menstrual irregularities with spironolactone. This documentation is critical for prior authorization success.

For post-MI HFrEF patients, cite the EPHESUS trial and ACC/AHA Class I recommendation when submitting a prior auth — payers typically accept guideline-backed clinical necessity.

Consider writing the prescription with "Dispense as written" only if brand Inspra is clinically necessary — generic is preferred in most cases due to equivalent efficacy and lower patient cost.

Cost Barriers and What Providers Can Offer

For uninsured patients, retail cash price for generic Eplerenone runs $90–$145 for a 30-day supply without a discount card. With GoodRx or SingleCare, prices drop to $17–$22 — a substantial reduction. Educating patients about discount programs at the time of prescribing can prevent them from going without their medication.

Practical tools to keep in your practice:

GoodRx and SingleCare coupons (printable or available via app) — keep a QR code visible in exam rooms for uninsured patients

NeedyMeds.org and RxAssist — for patients who may qualify for patient assistance programs

Mail-order pharmacy guidance — for long-term patients, 90-day mail-order fills offer better cost efficiency and uninterrupted supply

Pharmacy-Level Availability Issues

When patients report that their pharmacy is out of Eplerenone, consider these provider-side interventions:

Direct patients to use medfinder for providers — a real-time pharmacy availability tool that identifies which pharmacies near the patient currently have Eplerenone in stock, eliminating the need for time-consuming phone calls from your office.

Be prepared to electronically transfer the prescription to a different pharmacy on short notice — patients responding to availability information need the flexibility to fill at a different location.

For post-MI patients within the first 30 days of initiating therapy, a brief supply of samples can bridge any gap — check if your practice has Eplerenone or Inspra samples available.

When to Consider Therapeutic Substitution

Spironolactone remains a pharmacologically reasonable alternative in many HFrEF patients when Eplerenone is inaccessible. Key clinical considerations before switching:

Spironolactone is non-selective — higher rates of gynecomastia (approximately 9–10% in men at therapeutic doses), breast tenderness, and menstrual irregularities

Dose equivalence is not 1:1 — consult formulary conversion references before substituting

Both drugs require potassium and creatinine monitoring — frequency is the same

Spironolactone may be less tolerated in male patients; if the patient was originally switched to Eplerenone due to side effects, reverting is generally not recommended

Potassium Monitoring Requirements

Eplerenone carries a meaningful risk of hyperkalemia, particularly in patients with renal impairment, diabetes, or those on concurrent ACE inhibitors or ARBs. The FDA-approved labeling recommends serum potassium and creatinine measurement before initiation, within one week of starting therapy or dose change, and at one month. Patients on concurrent moderate CYP3A4 inhibitors require dose adjustment (maximum 25 mg once daily for post-MI HF patients).

Summary: Provider Action Items

Proactively document Eplerenone necessity over spironolactone to facilitate prior auth

Educate patients about GoodRx/SingleCare for cash pricing ($17–$22/month)

Recommend medfinder for real-time pharmacy availability search when patients report access issues

Be ready to e-prescribe to a different pharmacy when availability data identifies an in-stock location

Reserve therapeutic substitution to spironolactone for situations where Eplerenone truly cannot be sourced within a clinically safe time window